• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/2/21 1:46:38 PM ET
    $CYAD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CYAD alert in real time by email
    SC 13G/A 1 celyad13ga2_123120.htm

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    ( Amendment No. )*

    Celyad SA

    (Name of Issuer)

    American Depositary Receipt

    (Title of Class of Securities)

    151205200

    (CUSIP Number) 

    December 31, 2020

    (Date of Event which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    x  Rule 13d-1(b)
    ¨  Rule 13d-1(c)
    ¨  Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
     

     

             
    CUSIP No. 151205200   13G   Page 2 of 4 Pages
             

     

             
    1.  

    NAMES OF REPORTING PERSONS

     

    Victory Capital Management Inc.


    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    13-2700161

       
    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    ¨
       
    3.   SEC USE ONLY
     
       
    4.   CITIZENSHIP OR PLACE OF ORGANIZATION
     
    New York
       

     

             
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH   5.  

    SOLE VOTING POWER
     
    943,351

      6.   SHARED VOTING POWER
     
    0
      7.   SOLE DISPOSITIVE POWER
     
    968,847
      8.   SHARED DISPOSITIVE POWER
     
    0

     

             
    9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    968,847
       
    10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨
       
    11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.95%
       
    12.   TYPE OF REPORTING PERSON (see instructions)

    IA
       
             
             
                     
     
     

     

             
    CUSIP No. 151205200   13G   Page 3 of 4 Pages
             

    Item 1.

      (a) Name of Issuer
    Celyad SA
         
      (b)

    Address of Issuer’s Principal Executive Offices

    Rue Edouard Belin 12

    Mont-Saint-Guibert C9 1435

         

    Item 2.

      (a) Name of Persons Filing
    Victory Capital Management Inc.
         
      (b)

    Address of the Principal Office or, if none, residence
    4900 Tiedeman Rd. 4th Floor

    Brooklyn, OH 44144

         
      (c) Citizenship
    New York
         
      (d) Title of Class of Securities
    American Depositary Receipt
         
      (e) CUSIP Number
    151205200
         

    Item 3.  If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
           
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
           
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(J).
           

    Item 4.  Ownership.

     
     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

             
      (a)   Amount beneficially owned:  968,847
             
      (b)   Percent of class:  6.95%
             
      (c)   Number of shares as to which the person has:
             
          (i)

    Sole power to vote or to direct the vote:  943,351

             
          (ii) Shared power to vote or to direct the vote:  0
             
          (iii) Sole power to dispose or to direct the disposition of:  968,847
             
          (iv)

    Shared power to dispose or to direct the disposition of:  0

    Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

             

    Item 5.  Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  ¨

    Item 6.  Ownership of More than Five Percent on Behalf of Another Person.

    The clients of Victory Capital Management Inc., including investment companies registered under the Investment Company Act of 1940 and separately managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the class of securities reported herein. No client has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5% of such class.

     

    Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     Not applicable

    Item 8.  Identification and Classification of Members of the Group.

     Not applicable.

    Item 9.  Notice of Dissolution of Group.

     Not applicable.

    Item 10.  Certification.

           
      (a)   The following certification shall be included if the statement is filed pursuant to §240.13d-1(b):
             
          By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.  
             
             
     
     

     

             
    CUSIP No. 151205200   13G   Page 4 of 4 Pages
           

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    2/2/2021

    Date

     

    /s/ Colin S. Kinney

    Signature

     

    Colin S. Kinney / Chief Compliance Officer

    Name/Title

     

     

    Get the next $CYAD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CYAD

    DatePrice TargetRatingAnalyst
    1/11/2022$20.00 → $11.00Overweight
    Wells Fargo
    8/6/2021$17.00 → $15.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CYAD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Celyad Oncology announces receipt of Nasdaq delisting notice

      MONT-SAINT-GUIBERT, Belgium, May 15, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology ((Euronext &, NASDAQ:CYAD) (the "Company"), is a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies. The Company had previously announced on April 4th, 2023, that The Nasdaq Stock Market ("Nasdaq") notified the Company on March 31st, 2023 that it failed to maintain the continued listing requirement under Nasdaq Listing Rule 5450(b)(1)(A) for the Nasdaq Global Market, which requires that a listed company's stockholders' equity be at least $10.0 million. Further, on April 19th, 2023, as announced by the Company on April 24th, 2023, the Company received a n

      5/15/23 4:01:00 PM ET
      $CYAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Celyad Oncology Announces Intent to Voluntarily Delist American Depository Shares From Nasdaq

      MONT-SAINT-GUIBERT, Belgium, May 05, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology ((Euronext &, NASDAQ:CYAD) (the "Company"), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today announced that its Board of Directors has approved the voluntary delisting of its American Depositary Shares representing ordinary shares ("ADSs") from the Nasdaq Global Market, termination of its American Depositary Receipt ("ADR") facility and deregistration with the U.S. Securities and Exchange Commission (the "SEC") upon satisfaction of the requirements for deregistration. The Company will continue to be listed on Euronext Brussels. In connection w

      5/5/23 1:00:00 AM ET
      $CYAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Celyad Oncology reports first quarter 2023 financial results and recent business highlights

      Presentation of updated data on our multiplex shRNA platform, which allows targeting of up to four genes simultaneouslyPublication of results from the THINK trial, which provided proof-of-concept of our NKG2D-based CAR T-cell approach MONT-SAINT-GUIBERT, Belgium, May 05, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology ((Euronext &, NASDAQ:CYAD) (the "Company"), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today reports its financial results for the first quarter of 2023 and provides an update on recent business developments. "Celyad Oncology is now fully committed to leveraging its expertise, know-how and intellectual p

      5/5/23 1:00:00 AM ET
      $CYAD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYAD
    SEC Filings

    See more
    • SEC Form 15F-12B filed by Celyad Oncology SA

      15F-12B - Celyad Oncology SA (0001637890) (Filer)

      2/9/24 6:07:27 AM ET
      $CYAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Celyad Oncology SA

      6-K - Celyad Oncology SA (0001637890) (Filer)

      1/17/24 6:33:58 AM ET
      $CYAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Celyad Oncology SA

      6-K - Celyad Oncology SA (0001637890) (Filer)

      12/21/23 6:19:56 AM ET
      $CYAD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYAD
    Financials

    Live finance-specific insights

    See more

    $CYAD
    Leadership Updates

    Live Leadership Updates

    See more
    • Celyad Oncology reports full year 2022 financial results and recent business highlights

      Starting in 2023, Celyad Oncology is now entirely focused on its new business strategy with one clear objective: help to overcome the current limitations of CAR-T approaches. It plans to do this via (i) strengthening of its research focus centered around NKG2D, B7-H6 and shRNA platforms; (ii) maximizing the value of its IP estate and (iii) driving innovation through strategic collaborations. MONT-SAINT-GUIBERT, Belgium, March 23, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology ((Euronext &, NASDAQ:CYAD) (the "Company"), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today announces its financial results for the fiscal year 2022 e

      3/23/23 5:01:00 PM ET
      $CYAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Celyad Oncology to announce full year 2022 financial results and host conference call

      MONT-SAINT-GUIBERT, Belgium, March 17, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology ((Euronext &, NASDAQ:CYAD) (the "Company"), a biotechnology company focused on the discovery and development of innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today announced that the Company will report full year 2022 financial and operating results on the evening of Thursday, March 23rd. Following the press release, the Company management will host a conference call on Friday, March 24th 2023 at 1 p.m. CET / 8 a.m. ET to discuss full year 2022 results and provide an update on the Company's recent changes and upcoming milestones. Participants may access the conference call by d

      3/17/23 5:01:00 PM ET
      $CYAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlights

      Enrollment ongoing in Phase 1 dose-escalation IMMUNICY-1 trial for lead shRNA-based allogeneic CAR T candidate, CYAD-211, for relapsed/refractory (r/r) multiple myeloma (MM)In July 2022, the U.S. Food and Drug Administration (FDA) lifted the clinical hold for the T-cell-inhibitory-molecule (TIM)-based allogeneic CAR T candidate CYAD-101 for metastatic colorectal cancer (mCRC)Company to increase strategic focus on collaborations related to broad intellectual property portfolioConference call and webcast scheduled for today, August 5th, at 2:00 p.m. CEST / 8:00 a.m. EDT MONT-SAINT-GUIBERT, Belgium, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA ((Euronext &, NASDAQ:CYAD) (the "Com

      8/5/22 1:00:00 AM ET
      $CYAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Celyad Oncology appoints Georges Rawadi as its new CEO

      MONT-SAINT-GUIBERT, Belgium, March 24, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology ((Euronext &, NASDAQ:CYAD) (the "Company"), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, is pleased to announce Georges Rawadi as its new Chief Executive Officer (CEO), effective as of March 23, 2023, with starting date April 17, 2023. Michel Lussier will continue to serve as Interim CEO until April 17 to facilitate transition. Georges Rawadi is a seasoned executive with over 20 years of experience in pharma/biotech, as research director, business developer, CEO and board member. He spent four years at Celyad Oncology (2014-2018) as Vice-Presi

      3/24/23 2:00:00 AM ET
      $CYAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Celyad Oncology Announces Leadership Updates

      MONT-SAINT-GUIBERT, Belgium, June 24, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA ((Euronext &, NASDAQ:CYAD) (the "Company"), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Board of Directors has named Hilde Windels as Chairwoman of the Board of Directors, effective immediately. Ms. Windels has been a member of the Board of Directors since May 2018. Ms. Windels serves on multiple boards in the life sciences industry and has been an executive in the sector from 1999 through 2021, serving primarily as Chief Financial Officer and, over the last five years, as Chief Execu

      6/24/22 1:05:00 AM ET
      $CYAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Celyad Oncology Announces First Quarter 2021 Financial Results and Recent Business Highlights

      Enrollment continues in second dose cohort of Phase 1 dose-escalation IMMUNICY-1 trial for lead shRNA-based allogeneic CAR T candidate, CYAD-211, for relapsed/refractory multiple myeloma (r/r MM); additional proof-of-concept data anticipated in second quarter 2021.Expansion segment of Phase 1 alloSHRINK trial evaluating allogeneic CYAD-101 administered concurrently with preconditioning chemotherapy for the treatment of advanced metastatic colorectal cancer (mCRC) ongoing; preliminary data expected in mid-2021.Phase 1b KEYNOTE-B79 trial evaluating CYAD-101 with KEYTRUDA® in patients with microsatellite stable mCRC expected to be initiated in first half of 2021. MONT-SAINT-GUIBERT, Belgiu

      5/6/21 4:01:00 PM ET
      $CYAD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYAD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Celyad Oncology SA (Amendment)

      SC 13D/A - Celyad Oncology SA (0001637890) (Subject)

      9/5/23 4:32:35 PM ET
      $CYAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Celyad Oncology SA (Amendment)

      SC 13D/A - Celyad Oncology SA (0001637890) (Subject)

      8/24/23 4:26:06 PM ET
      $CYAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Celyad SA

      SC 13D - Celyad Oncology SA (0001637890) (Subject)

      12/17/21 4:30:28 PM ET
      $CYAD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYAD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wells Fargo reiterated coverage on Celyad Oncology with a new price target

      Wells Fargo reiterated coverage of Celyad Oncology with a rating of Overweight and set a new price target of $11.00 from $20.00 previously

      1/11/22 6:56:48 AM ET
      $CYAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Celyad Oncology with a new price target

      HC Wainwright & Co. reiterated coverage of Celyad Oncology with a rating of Buy and set a new price target of $15.00 from $17.00 previously

      8/6/21 6:06:14 AM ET
      $CYAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Celyad Oncology with a new price target

      HC Wainwright & Co. reiterated coverage of Celyad Oncology with a rating of Buy and set a new price target of $17.00 from $18.00 previously

      5/10/21 6:11:08 AM ET
      $CYAD
      Biotechnology: Pharmaceutical Preparations
      Health Care